Gotham Therapeutics launched in New York with a $54 million Series A financing. The round was co-led by founding investor Versant Ventures, Forbion, and S.R. One.
Morphic Therapeutic has completed a $80 million Series B financing to fund the biotechnology company’s two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.
Artios Pharma received a financial boost from Pfizer, AbbVie and Novartis through an $84 million (£65 million) Series B funding.
Two companies that specialize in AI-backed drug development – Insilico Medicine and A2A Pharmaceuticals – are teaming up to take on the rare disease known as Duchene Muscular Dystrophy.
New York-based Kallyope and Danish company Novo Nordisk signed a research collaboration and option deal to discover novel therapeutics to treat obesity and diabetes.
Regeneron Pharmaceuticals Inc. announced a collaboration with rival drugmakers that will speed its effort to collect genetic information on 500,000 people in the UK Biobank database, a project the company believes could help accelerate new drug discovery and improve approval success rates.
Alnylam and Sanofi announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for rare genetic diseases.
GenScript Biotech Corp. – a leading global provider of gene synthesis services – announced an agreement to acquire 100 percent of the issued shares of CustomArray Inc., a privately held DNA microarray company.
Amgen and Novartis announced that they expanded their collaboration with the Banner Alzheimer’s Institute to launch a new clinical trial in Alzheimer’s.
Scientists launched a global initiative to map out and describe every cell in the human body in a vast atlas that could transform research.